Javascript must be enabled to continue!
Fostering a Culture of Health Innovation: A Review of Regulation and Integration of AI, Genomics, and Digital Therapeutics by the Ministry of Health
View through CrossRef
Background: The global health landscape is being redefined by a new era of emerging technologies, including artificial intelligence (AI), genomics, and digital therapeutics (DTx). The technologies hold the promise to shift healthcare from an episodic, reactive, and hospital-based system to a predictive, personalized, and participatory system. However, their incorporation in healthcare systems raises severe problems for regulation, ethics, equity, and implementation. The national Ministry of Health (MoH) is at the center of coordinating this transition, but its role must change beyond traditional roles such that it actively encourages a culture of responsible innovation.
Aim: The purpose of this narrative review is to synthesize existing literature for critically analyzing the multidimensional role of the MoH in spearheading the integration of AI, genomics, and DTx.
Methods: Systematic peer-reviewed and grey literature search between 2010-2024 on PubMed, Scopus, Web of Science, and WHO, FDA, and other regulatory sources. Thematic analysis with results structured around three core domains: governance, infrastructure, and adoption.
Results: The review suggests that holistic strategies are necessary for successful integration. In regulation, MoHs must implement flexible, risk-appropriate regulatory frameworks for adaptive AI and DTx that ensure ethical exploitation of genomic information. State investment in underlying infrastructure, such as national data governance arrangements and genomic biobanks, is needed. New value-based payment models, upskilling of human resources, and national clinical guidelines need to be fostered to drive adoption.
Conclusion: MoH is the indispensable conductor of health innovation. Through adopting a pro-reform, integrated stewardship strategy, MoHs can unlock the power of AI, genomics, and DTx to build more equitable, efficient, and resilient health systems, ultimately to speed progress towards Universal Health Coverage.
Maktab Mutlaq Al-Injaz for Academic Services
Munaa Mulahi Gazi Alharbi
Nasrah Saadi Raga Alshammari
Afra Radi Hamad Alaglan
Mohammed Obaidallah Alshammari
Majed Aseed Rashed Alshammari
Maha Saeed Raja Rmal
Basmah Ghanem Rubayyi Alshammari
Ibrahim Khulaif Alshammari
Taghreed Hamoud Ali Alshammari
Ola Hamoud Ali Alshammari
Najah Hamoud Ali Alshammari
Tahani Nazal Naqaa Alshammari
Nashmeyah Hmadian Al Rashedy
Sabahah Saad Dabis Alazmi
Amnah Menwer Fayed Alrashidi
Abdulmajeed Mudhi Al Shammari
Reem Hamad Abdullah Alshammari
Title: Fostering a Culture of Health Innovation: A Review of Regulation and Integration of AI, Genomics, and Digital Therapeutics by the Ministry of Health
Description:
Background: The global health landscape is being redefined by a new era of emerging technologies, including artificial intelligence (AI), genomics, and digital therapeutics (DTx).
The technologies hold the promise to shift healthcare from an episodic, reactive, and hospital-based system to a predictive, personalized, and participatory system.
However, their incorporation in healthcare systems raises severe problems for regulation, ethics, equity, and implementation.
The national Ministry of Health (MoH) is at the center of coordinating this transition, but its role must change beyond traditional roles such that it actively encourages a culture of responsible innovation.
Aim: The purpose of this narrative review is to synthesize existing literature for critically analyzing the multidimensional role of the MoH in spearheading the integration of AI, genomics, and DTx.
Methods: Systematic peer-reviewed and grey literature search between 2010-2024 on PubMed, Scopus, Web of Science, and WHO, FDA, and other regulatory sources.
Thematic analysis with results structured around three core domains: governance, infrastructure, and adoption.
Results: The review suggests that holistic strategies are necessary for successful integration.
In regulation, MoHs must implement flexible, risk-appropriate regulatory frameworks for adaptive AI and DTx that ensure ethical exploitation of genomic information.
State investment in underlying infrastructure, such as national data governance arrangements and genomic biobanks, is needed.
New value-based payment models, upskilling of human resources, and national clinical guidelines need to be fostered to drive adoption.
Conclusion: MoH is the indispensable conductor of health innovation.
Through adopting a pro-reform, integrated stewardship strategy, MoHs can unlock the power of AI, genomics, and DTx to build more equitable, efficient, and resilient health systems, ultimately to speed progress towards Universal Health Coverage.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Access Denied
Access Denied
Introduction
As social-distancing mandates in response to COVID-19 restricted in-person data collection methods such as participant observation and interviews, researchers turned t...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
The influence of micro influencers and digital marketing on product purchasing decisions at tiktok shop in bengkulu city
The influence of micro influencers and digital marketing on product purchasing decisions at tiktok shop in bengkulu city
THE INFLUENCE OF MICRO-INFLUENCERS AND DIGITAL MARKETING ON PURCHASE DECISIONS OF TIKTOK SHOP CUSTOMERS IN BENGKULU CITY
Andhes Tiani Putri, Meylaty F
12Faculty Of Economic
E...
Genomics and society: four scenarios for 2015
Genomics and society: four scenarios for 2015
This paper develops four alternative scenarios depicting possible futures for genomics applications within a broader social context. The scenarios integrate forecasts for future ge...

